Physician profile
Jeffrey Jones
NPI 1942226824
$1,094.22
in general payments reported to CMS, 2019-2025
15 companies · $317 in 2025
The $317 reported for 2025 was more than what 89% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $88.68 · 2021: $95.17 · 2022: $71.62 · 2023: $124 · 2024: $123 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548 · Education: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.30 |
| Education | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $234.52 | 2024-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $208.69 | 2019-2022 | |
| Ardelyx, INC. | $127.08 | 2023-2025 | Ibsrela |
| Portola Pharmaceuticals, LLC | $116.07 | 2019 | |
| Abbvie INC. | $77.65 | 2021-2025 | |
| Pfizer INC. | $67.95 | 2021 | |
| Gilead Sciences, INC. | $64.38 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.42 | 2019-2023 | Xifaxan |
| Genzyme Corporation | $43.37 | 2023 | |
| Phathom Pharmaceuticals, INC. | $28.10 | 2025 | Voquezna |
| Biotissue Holdings INC. | $20.68 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.66 | 2020 | |
| Celltrion USA INC. | $16.10 | 2024 | Zymfentra |
| Melinta Therapeutics, LLC | $14.53 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.